RenovoRx announces first patient enrolled at UNMC for Phase III TIGeR-PaC trial

RenovoRx pharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the first patient has been enrolled at the University of Nebraska Medical Center, UNMC, in RenovoRx’s ongoing pivotal Phase III TIGeR-PaC clinical trial for Locally Advanced Pancreatic Cancer, LAPC. The TIGeR-PaC study is using RenovoRx’s TAMP therapy platform, to evaluate the Company’s first product candidate, RenovoGem, which is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine across the arterial wall near the tumor site to bathe the target tumor. The study is comparing treatment with TAMP in LAPC to the current standard-of-care.